Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemELDC7559Cat.No.:HY-111674CASNo.:2407782-01-6分?式:C??H??N?O?分?量:349.38作?靶點:Pyroptosis作?通路:Apoptosis;Immunology/Inflammation儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數據體外實驗DMSO:100mg/mL(286.22mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM2.8622mL14.3111mL28.6221mL5mM0.5724mL2.8622mL5.7244mL10mM0.2862mL1.4311mL2.8622mL請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復凍融造成的產品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內使?，-20°C儲存時，請在1個?內使?。體內實驗請根據您的實驗動物和給藥?式選擇適當的溶解?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結果的可靠性，澄的儲備液可以根據儲存條件，適當保存；體內實驗的?作液，建議您現?現配，當天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現沉淀、析出現象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.08mg/mL(5.95mM);Clearsolution1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.08mg/mL(5.95mM);Clearsolution3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(5.95mM);ClearsolutionBIOLOGICALACTIVITY?物活性LDC7559?種消?素D(GSDMD)的抑制劑，通過抑制中性粒細胞胞外殺?絡(NET)后期階段?發揮作?。IC50&TargetGasderminD[1].體外研究LDC7559(1and5μM)inhibitsIL-1βreleaseuponinflammasomeactivation,andsignificantlyblocksthelethaleffectofbothhumanandmurineGSDMDNTdomainstransfectedintoHEK293Tcells[3].LDC7559functionsdirectlythroughblockingtheactivityoftheGSDMDNTdomain,ratherthaninterferingwiththeactivationandcleavageprocess[3].戶使?本產品發表的科研?獻?Elife.2021Jul21;10:e68755.?Elife.2021Jul21;10:e68755.?EurJImmunol.2022Oct17.?FASEBJ.2020Oct;34(10):14024-14041.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].SpelL,etal.GasderminDopensthewayforNETs.NatRevRheumatol.2018Dec;14(12):690-692.[2].SollbergerG,etal.GasderminDplaysavitalroleinthegenerationofneutrophilextracellulartraps.SciImmunol.2018Aug24;3(26).pii:eaar6689.[3].AnkitPandeya,etal.GasderminD(GSDMD)asaNewTargetfortheTreatmentofInfection.Medchemcomm.2019Apr4;10(5):660-667.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchus